Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
about
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancerIs there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesElectron paramagnetic resonance highlights that the oxygen effect contributes to the radiosensitizing effect of paclitaxelThe effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancerInhibitor of MYC identified in a Kröhnke pyridine libraryClinical Translation of Nanomedicine.Taxol biosynthesis and molecular geneticsPreparation, pharmacokinetics, biodistribution, antitumor efficacy and safety of Lx2-32c-containing liposomePaclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.Cremophor-induced lupus erythematosus-like reaction with taxol administration: a case report and review of the literature.Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges.One-step fabrication of polymeric Janus nanoparticles for drug deliveryHydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterizationDifferential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range.A cell-based pharmacokinetics assay for evaluating tubulin-binding drugsHypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulationPaclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.CD44 Signaling Mediates High Molecular Weight Hyaluronan-induced Anti-hyperalgesia.Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.A synergistic effect of Cremophor and beta glucosylceramide to exert liver and sugar protection.
P2860
Q24657308-4512ABA1-1FD5-4AD4-A580-02B5A30EEE98Q26766180-1E734C3E-3E47-4D9B-9707-4BE148830309Q28481293-46B3761B-3C98-4CFA-86CF-F5CD88B42EF9Q28540889-65FA44E3-D74F-4B25-8835-679DBE719AD1Q28656132-D4DB824D-7167-42D5-8BEC-CF5912D009FCQ30355939-1685BCD1-E261-4FCD-A419-C215D7559DFDQ33630392-F1CEC99E-BEBB-4335-BAFB-7C22D0F84042Q34702599-3E0FC3B5-2F94-4E84-999F-075CD1704631Q35166688-F25321FC-CA7F-4DAD-9F07-D7FAAA4DF986Q35574188-B1A08F47-C6C4-48E1-A060-AA8D53833EE4Q36183605-1B44EF83-ED1B-4850-AE35-B637D6CA59FEQ36638801-08DAE339-2FC7-44D8-A820-9EAC5ADB0F58Q36868666-5F4ADFC9-FC45-4B24-A9FE-0C26BEF64F57Q37549416-87D4E41E-EE42-4023-A6DB-EB84DBC86EA3Q38561970-8443F1E6-6F32-47FF-849A-51BCC26CAE6BQ39215897-86A3830A-ADB0-4FDF-9390-B3C351698645Q39430827-D5AB1FBE-6DDA-4FFE-92C5-E43CEE82F88BQ46134808-D7278BAE-A3A6-4C2B-851E-F4845ADAD48BQ54978314-C800DF40-305F-4C66-9B4B-59EF4F0FA415Q55014958-2AB519E7-5C86-4B97-BEC8-C0961652F5C8
P2860
Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
@en
type
label
Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
@en
prefLabel
Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
@en
P2093
P1476
Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
@en
P2093
P304
P577
1993-01-01T00:00:00Z